Pertuzumab and trastuzumab: the rationale way to synergy

It has now been 15 years since the HER2-targeted monoclonal antibody trastuzumab was introduced in clinical and revolutionized the treatment of HER2-positive breast cancer patients. Despite this achievement, most patients with HER2-positive metastatic breast cancer...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Anais da Academia Brasileira de Ciências
Auteurs principaux: Sandrine Richard, Frédéric Selle, Jean-Pierre Lotz, Ahmed Khalil, Joseph Gligorov, Daniele G. Soares
Format: Artigo
Langue:Inglês
Publié: Academia Brasileira de Ciências 2016
Sujets:
Multidisciplinaria (Ciencias Naturales y Exactas)
HER2
pertuzumab
trastuzumab
dimerization
Breast cancer
Accès en ligne:https://www.redalyc.org/articulo.oa?id=32746362012
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires